Hims & Hers Health (NYSE:HIMS) Downgraded to “In-Line” at Imperial Capital

Imperial Capital lowered shares of Hims & Hers Health (NYSE:HIMS) from an outperform rating to an in-line rating in a research note published on Friday, Marketbeat reports.

HIMS has been the topic of a number of other research reports. Canaccord Genuity Group upped their target price on shares of Hims & Hers Health from $20.00 to $24.00 and gave the company a buy rating in a research report on Wednesday, May 22nd. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Hims & Hers Health from $16.00 to $23.00 and gave the stock a hold rating in a research report on Wednesday. Piper Sandler restated a neutral rating and set a $18.00 price target on shares of Hims & Hers Health in a research note on Tuesday, August 6th. Bank of America lifted their price objective on Hims & Hers Health from $22.00 to $26.00 and gave the company a buy rating in a research note on Thursday, June 13th. Finally, TD Cowen increased their target price on Hims & Hers Health from $15.00 to $25.00 and gave the stock a buy rating in a research note on Thursday, July 11th. Eight analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Hims & Hers Health has an average rating of Hold and an average target price of $20.00.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS traded up $0.11 during trading on Friday, hitting $15.96. 8,244,545 shares of the company were exchanged, compared to its average volume of 7,900,966. The company has a fifty day moving average price of $21.12 and a 200-day moving average price of $15.96. The firm has a market capitalization of $3.43 billion, a PE ratio of -1,596.00 and a beta of 1.08. Hims & Hers Health has a 12-month low of $5.65 and a 12-month high of $25.74.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02. The company had revenue of $315.65 million for the quarter, compared to analyst estimates of $302.43 million. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. Hims & Hers Health’s revenue was up 51.8% on a year-over-year basis. During the same period in the previous year, the business posted ($0.03) EPS. Research analysts anticipate that Hims & Hers Health will post 0.2 earnings per share for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 2,503 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $12.33, for a total transaction of $30,861.99. Following the sale, the insider now owns 159,357 shares of the company’s stock, valued at $1,964,871.81. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, insider Soleil Boughton sold 2,503 shares of the business’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $12.33, for a total value of $30,861.99. Following the completion of the sale, the insider now directly owns 159,357 shares of the company’s stock, valued at approximately $1,964,871.81. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Michael Chi sold 7,500 shares of the company’s stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $24.50, for a total value of $183,750.00. Following the completion of the sale, the insider now directly owns 185,326 shares of the company’s stock, valued at $4,540,487. The disclosure for this sale can be found here. Insiders have sold a total of 980,907 shares of company stock worth $19,445,689 over the last ninety days. Corporate insiders own 17.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC grew its stake in shares of Hims & Hers Health by 103.2% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 43,662 shares of the company’s stock valued at $389,000 after purchasing an additional 22,170 shares during the last quarter. Custom Index Systems LLC acquired a new position in Hims & Hers Health in the 4th quarter valued at $132,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Hims & Hers Health by 5.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,335 shares of the company’s stock worth $261,000 after buying an additional 1,561 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Hims & Hers Health by 30.7% in the 4th quarter. Russell Investments Group Ltd. now owns 167,328 shares of the company’s stock worth $1,489,000 after acquiring an additional 39,337 shares during the period. Finally, Certuity LLC purchased a new stake in shares of Hims & Hers Health in the fourth quarter valued at about $109,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.